Search Results - "Pankey, George A"
-
1
IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults
Published in Clinical infectious diseases (15-04-2012)“…Evidence-based guidelines for the diagnosis and initial management of suspected acute bacterial rhinosinusitis in adults and children were prepared by a…”
Get full text
Journal Article -
2
Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii
Published in International journal of antimicrobial agents (01-05-2019)“…•New antimicrobials are needed for carbapenem-resistant Acinetobacter baumannii.•Nisin is an FDA-approved antibacterial peptide currently used as a food…”
Get full text
Journal Article -
3
In vitro Synergistic Activity of Caspofungin Plus Polymyxin B Against Fluconazole-Resistant Candida glabrata
Published in The American journal of the medical sciences (01-03-2016)“…Abstract Background Candida species account for most invasive fungal infections, and the emergence of fluconazole and caspofungin resistance is problematic…”
Get full text
Journal Article -
4
Cryptococcosis in Human Immunodeficiency Virus-Negative Patients in the Era of Effective Azole Therapy
Published in Clinical infectious diseases (01-09-2001)“…We conducted a case study of human immunodeficiency virus (HIV)-negative patients with cryptococcosis at 15 United States medical centers from 1990 through…”
Get full text
Journal Article Conference Proceeding -
5
In Vitro Synergy of Ciprofloxacin and Gatifloxacin against Ciprofloxacin-Resistant Pseudomonas aeruginosa
Published in Antimicrobial Agents and Chemotherapy (01-07-2005)“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text
Journal Article -
6
The Importance of Bactericidal Drugs: Future Directions in Infectious Disease
Published in Clinical infectious diseases (01-11-2004)“…Background. Although a considerable amount of research has gone into the study of the role of bactericidal versus bacteriostatic antimicrobial agents in the…”
Get full text
Journal Article -
7
The detection of synergy between meropenem and polymyxin B against meropenem-resistant Acinetobacter baumannii using Etest® and time-kill assay
Published in Diagnostic microbiology and infectious disease (01-02-2009)“…Abstract Time-kill assay and Etest testing for synergy of meropenem (MER) (1× MIC) plus polymyxin B (1/4, 1/2, and 1× MIC) were performed against 8 genetically…”
Get full text
Journal Article -
8
Tigecycline
Published in Journal of antimicrobial chemotherapy (01-09-2005)“…New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly…”
Get full text
Journal Article -
9
A Man Presenting with Nodules on Hands and Elbows
Published in Clinical infectious diseases (15-04-2009)Get full text
Journal Article -
10
In vitro antibacterial activity of tigecycline against resistant Gram-negative bacilli and enterococci by time–kill assay
Published in Diagnostic microbiology and infectious disease (01-07-2009)“…Abstract This time–kill study was performed with 65 genetically unique clinical isolates of Gram-negative bacilli and enterococci to further define the…”
Get full text
Journal Article -
11
Performance of the T2Bacteria Panel for Diagnosing Bloodstream Infections: A Diagnostic Accuracy Study
Published in Annals of internal medicine (18-06-2019)“…Blood cultures, the gold standard for diagnosing bloodstream infections (BSIs), are insensitive and limited by prolonged time to results. The T2Bacteria Panel…”
Get full text
Journal Article -
12
Evaluation of the in vitro interaction of fosfomycin and meropenem against metallo-β-lactamase–producing Pseudomonas aeruginosa using Etest and time-kill assay
Published in Journal of investigative medicine (01-02-2021)“…Pseudomonas aeruginosa is a nosocomial pathogen containing various resistance mechanisms. Among them, metallo-β-lactamase (MBL)–producing Pseudomonas are…”
Get full text
Journal Article -
13
In vitro interaction of fluconazole and trimethoprim–sulfamethoxazole against Candida auris using ETEST and checkerboard methods
Published in Journal of investigative medicine (01-01-2021)“…Candida auris was discovered in 2009 and has rapidly emerged as a serious public health threat with cases reported in over 20 countries worldwide. As of May 8,…”
Get full text
Journal Article -
14
Comparison of 3 Etest® methods and time-kill assay for determination of antimicrobial synergy against carbapenemase-producing Klebsiella species
Published in Diagnostic microbiology and infectious disease (01-11-2013)“…Abstract Increasing global antibiotic resistance has resulted in more use of antibiotic combinations. There is a lack of a gold standard for in vitro testing…”
Get full text
Journal Article -
15
Tigecycline in Critical Care
Published in Critical care clinics (01-04-2008)“…The emergence and spread of multidrug resistance in many pathogenic bacterial species is increasing at an alarming rate, especially with hospital-acquired…”
Get full text
Journal Article -
16
In vitro synergy with fluconazole plus doxycycline or tigecycline against clinical Candida glabrata isolates
Published in Medical mycology (Oxford) (01-01-2019)“…Abstract Candida species, traditionally viewed as opportunistic agents, are increasingly seen as a cause of infection in hospitalized patients. Treatment…”
Get full text
Journal Article -
17
Tuberculous Otomastoiditis
Published in Microbiology spectrum (01-12-2016)“…Tuberculous otitis media and mastoiditis, or tuberculous otomastoiditis, is a rare but well-described infectious process occasionally affecting individuals in…”
Get more information
Journal Article -
18
Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae
Published in Diagnostic microbiology and infectious disease (01-08-2011)“…Abstract Polymyxin B (PB) plus meropenem (MER) or rifampin (RIF) was tested by Etest® method and time-kill assay (TKA) against 14 genetically unique clinical…”
Get full text
Journal Article -
19
Practice Guidelines for Diseases Caused by Aspergillus
Published in Clinical infectious diseases (01-04-2000)Get full text
Journal Article -
20
Update on the emerging role of telavancin in hospital-acquired infections
Published in Therapeutics and clinical risk management (01-01-2015)“…Telavancin is a lipoglycopeptide that has activity against Gram-positive aerobic and anaerobic bacteria. It has activity against methicillin-resistant…”
Get full text
Journal Article